研究单位：[1]Xiangya Hospital of Central South University[2]The First People's Hospital of Changde,Changde,Hunan,China,410008[3]Changsha Fourth Hospital,Changsha,Hunan,China,410008[4]XiangYa School of Medicine,Changsha,Hunan,China,410008[5]Zhangjiajie People's Hospital,Changsha,Hunan,China,410008[6]Changsha Central Hospital,Changsha,Hunan,China[7]Changsha Hospital of Traditional Chinese Medicine (Changsha Eighth Hospital),Changsha,Hunan,China[8]Chenzhou First People's Hospital,Chenzhou,Hunan,China,410008[9]Hunan University of Medicine Hospital,Huaihua,Hunan,China,410008[10]The Central Hospital of Shaoyang,Shaoyang,Hunan,China,410008[11]Xiangtan Central Hospital,Xiangtan,Hunan,China,410008[12]The Central Hospital of Yongzhou,Yongzhou,Hunan,China,410008[13]Yueyang Central Hospital,Yueyang,Hunan,China[14]Zhuzhou Central Hospital,Zhuzhou,Hunan,China,410008[15]Jiangxi Provincial People's Hospital,Nanchang,Jiangxi,China[16]Chengdu Fifth Pepole's Hospital,Chengdu,Sichuan,China[17]Xuanwu Hospital Capital Medical University,Beijing,China
Spontaneous cerebral hemorrhage (SICH) is a hemorrhage caused by the rupture of a blood vessel within the brain parenchyma that is non-traumatic. Its rapid onset and dangerous condition seriously threaten human health; it accounts for about 15% of strokes and 50% of stroke-related mortality. Hunan Province is recognized as one of the high incidence areas of cerebral hemorrhage in the world; according to statistics, the direct economic loss caused by cerebral hemorrhage in Hunan Province is more than 1 billion yuan per year, which should be paid great attention. A 30-day follow-up study of large-volume cerebral hemorrhage (defined as supratentorial hemorrhage greater than 30 ml, infratentorial greater than 5 ml, and thalamus and cerebellum greater than 15 ml) found that the morbidity and mortality rate of ICH with hemorrhage of 30-60 ml was as high as 44-74%, while the morbidity and mortality rate of ICH with hemorrhage of <30 ml was 19% and that of >60 ml was 91%. According to studies, the occurrence of hematoma occupancy and malignant cerebral edema in large-volume cerebral hemorrhage can lead to secondary malignant intracranial pressure elevation and subsequent secondary brain injury, which are the main factors of high morbidity and mortality and poor prognosis in patients with large-volume cerebral hemorrhage. Clinical monitoring and management is the key to treatment, and despite aggressive surgical treatment and anti-brain edema therapy, a large number of patients progress to malignant brain edema disease, leading to poor outcomes. Therefore, this project intends to conduct a multicenter clinical trial of non-invasive monitoring of large volume cerebral hemorrhage on the curtain in the Hunan region to explore the impact of non-invasive brain edema monitoring management based on bioelectrical impedance technology on patient prognosis; and to explore early biomarkers of malignant brain edema through metabolomic analysis and the mechanism of malignant brain edema occurrence through multi-omic analysis to provide data support for the clinical treatment application of malignant brain edema.
